Active not recruitingOBSERVATIONAL

MIF Involvement in AML

This research aims to understand how a protein called MIF might be involved in adult Acute Myeloid Leukemia (AML). Researchers are looking at blood and bone marrow samples from patients with AML, both when they are first diagnosed and during their treatment journey. They want to find out if certain AML cells produce too much MIF and what effect this might have. This includes seeing if MIF levels could help predict how a patient might respond to treatment or if it sticks around even when the cancer is in remission. The study also involves lab work with animal models to explore new ways to target MIF with medicines. Ultimately, the goal is to develop better treatments for AML.

At a glance

Status

Active not recruiting

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrolment target

186

Start

07 Jul 2019

Estimated completion

01 Jun 2025

Acute Myeloid Leukemia

What is this study about?

This study is like detective work, trying to understand a complex type of blood cancer called Acute Myeloid Leukemia (AML). Researchers are specifically focusing on a protein called MIF and how it might play a role in this disease. They believe that understanding MIF better could lead to new ways to diagnose, predict, and treat AML.

The main goals are to figure out if certain AML cells produce too much MIF and if this affects how the disease behaves. They'll be looking at samples collected from patients at different stages: when they are first diagnosed, after their first round of treatment, when they are in remission, and if the cancer returns. They will also look at the specific genetic make-up of the cancer cells. Another important part of this research is to see if any problematic cells that make a lot of MIF remain in the body even when the cancer appears to be gone (in remission). This could help predict if the cancer might come back.

Beyond studying patient samples, the researchers are also conducting lab experiments using special mice. These mice are given human AML cells to create a model for the disease. The scientists will then test different ways to block or reduce MIF in these models, hoping to find new treatments. They are also trying to understand exactly how MIF works within these cancer cells and how it communicates with other cells in the bone marrow, which is where blood cells are made.

Key takeaways

This study explores the role of a protein called MIF in adult Acute Myeloid Leukemia (AML).
It uses routine blood and bone marrow samples from patients, not extra procedures.
Researchers hope to find out if MIF levels can predict disease activity or treatment success.
No new treatments are given as part of this study.
The findings could help develop better AML treatments in the future.

Who may be eligible?

To be considered for this study, you must be an adult aged 18 or older who has recently been diagnosed with Acute Myeloid Leukemia (AML). You would need to be a patient at either Saint Antoine Hospital or Tours University Hospital.

Before joining, you will be asked to read and sign an informed consent form. This form explains the study in detail and ensures you understand what's involved before you agree to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you recently been diagnosed with Acute Myeloid Leukemia (AML)?
Are you a patient at Saint Antoine Hospital or Tours University Hospital?
Are you willing to provide written consent to participate?

Answer every question to see your result.

What does participation involve?

This study is an 'observational' study, which means you won't be given any new treatments or medicines as part of the research. Instead, researchers will be collecting and studying samples that are already being taken as part of your routine medical care for AML. This includes blood and bone marrow samples taken at diagnosis, after your first treatment, when your cancer is in remission, and if it unfortunately returns.

There are no extra visits or assessments specifically for this study beyond your standard medical appointments. The researchers will simply use the samples collected from your regular care. The length of your participation will depend on your treatment journey, as samples are collected at different stages of your disease. You are free to withdraw from the study at any time.

Potential risks and benefits

Since this is an observational study that uses samples from your standard medical care, there are no additional medical risks from participating. Your medical treatment will not be changed. The potential benefit is that the information gained from this research could help scientists better understand AML and potentially lead to new and more effective treatments for others in the future. You have the right to withdraw from the study at any time, without it affecting your medical care.

Locations (1)

Laboratoire d'hématologie Hôpital Saint Antoine
Verified postcode
Paris, France

Common questions

What is MIF?

MIF stands for Macrophage Migration Inhibitory Factor. It's a protein that plays a role in our immune system, and researchers are trying to understand its role in certain cancers like AML.

Will I receive new treatment in this study?

No, this is an 'observational' study. You will receive your standard AML treatment, and the researchers will simply study samples from that treatment journey.

What kind of samples will be collected?

Researchers will use blood and bone marrow samples that are already being collected as part of your routine care for AML.

Will my personal information be kept private?

Yes, all your personal and medical information will be kept confidential and used only for research purposes, protecting your privacy.

What is the main goal of this study?

The main goal is to better understand how the MIF protein is involved in AML, hoping this knowledge will lead to better ways to diagnose and treat the disease in the future.